Tarsus Pharmaceuticals, an Irvine, Calif.-based clinical-stage biopharmaceutical company, closed a $60m in Series B financing.
The round was led by Vivo Capital and included Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners, and Horowitz Group.
The company will use the funds to initiate a Phase 2b/3 trial in the U.S. of their lead product TP-03 for Demodex blepharitis and fuel Phase 1 and 2 development of other clinical programs.
Led by Bobby Azamian, MD, PhD, CEO, Tarsus is a clinical-stage biopharmaceutical company founded to bring innovative therapies to a range of diseases in need of better solutions, starting with Demodex blepharitis and eye care. TP-03 is a topical ophthalmic that targets an underlying cause of blepharitis and has the potential to be the first-ever drug treatment for this condition. The company’s product pipeline includes additional indications in eye care and other areas of high unmet clinical need.